Kamada (KMDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Kamada for the company's overall valuation and market capitalisation.
Kamada - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kamada Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kamada ranked by their cash flow conversion efficiency. Explore KMDA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Juheshun New Material Co Ltd
SHG:605166
|
-0.008x |
|
Buana Listya Tama Tbk PT
JK:BULL
|
0.026x |
|
First Carolina Financial Services, Inc.
NYSE:FCBM
|
0.031x |
|
San Fang Chemical Industry Co Ltd
TW:1307
|
-0.020x |
|
Equinox India Developments Ltd
NSE:IBREALEST
|
0.001x |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
0.006x |
|
Zhejiang Baida Precision Mnfg
SHG:603331
|
0.085x |
|
China Datang Corporation Renewable Power Co. Limited
STU:DT7
|
0.046x |
Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)
The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. View Kamada (KMDA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA259.46 Million ≈ $695.61K |
ILA47.59 Million ≈ $127.60K |
0.183x | +937.34% |
| 2023-12-31 | ILA244.02 Million ≈ $654.21K |
ILA4.32 Million ≈ $11.57K |
0.018x | -89.11% |
| 2022-12-31 | ILA176.02 Million ≈ $471.90K |
ILA28.59 Million ≈ $76.64K |
0.162x | +425.62% |
| 2021-12-31 | ILA176.82 Million ≈ $474.06K |
ILA-8.82 Million ≈ $-23.64K |
-0.050x | -146.63% |
| 2020-12-31 | ILA178.64 Million ≈ $478.92K |
ILA19.11 Million ≈ $51.22K |
0.107x | -47.51% |
| 2019-12-31 | ILA135.32 Million ≈ $362.79K |
ILA27.57 Million ≈ $73.92K |
0.204x | +117.11% |
| 2018-12-31 | ILA112.38 Million ≈ $301.28K |
ILA10.55 Million ≈ $28.27K |
0.094x | +115.90% |
| 2017-12-31 | ILA89.49 Million ≈ $239.92K |
ILA3.89 Million ≈ $10.43K |
0.043x | +52.93% |
| 2016-12-31 | ILA66.74 Million ≈ $178.94K |
ILA1.90 Million ≈ $5.09K |
0.028x | +114.74% |
| 2015-12-31 | ILA72.51 Million ≈ $194.39K |
ILA-13.98 Million ≈ $-37.48K |
-0.193x | -57.44% |
| 2014-12-31 | ILA80.99 Million ≈ $217.14K |
ILA-9.92 Million ≈ $-26.59K |
-0.122x | -185.86% |
| 2013-12-31 | ILA89.97 Million ≈ $241.21K |
ILA-3.85 Million ≈ $-10.33K |
-0.043x | +85.28% |
| 2012-12-31 | ILA28.39 Million ≈ $76.12K |
ILA-8.26 Million ≈ $-22.15K |
-0.291x | -801.65% |
| 2011-12-31 | ILA22.67 Million ≈ $60.79K |
ILA940.36K ≈ $2.52K |
0.041x | -89.67% |
| 2010-12-31 | ILA26.49 Million ≈ $71.01K |
ILA10.63 Million ≈ $28.50K |
0.401x | +192.43% |
| 2009-12-31 | ILA30.15 Million ≈ $80.83K |
ILA-13.09 Million ≈ $-35.10K |
-0.434x | +56.84% |
| 2008-12-31 | ILA12.64 Million ≈ $33.89K |
ILA-12.72 Million ≈ $-34.11K |
-1.006x | -456.76% |
| 2007-12-31 | ILA69.57 Million ≈ $186.51K |
ILA-12.57 Million ≈ $-33.71K |
-0.181x | -- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more